

Supplementary Table 3. Incidence of metachronous gastric cancer according to demographic factors in each study

Variable	Total	Hanaoka et al. [21], 2010	Han et al. [19], 2011	Maehata et al. [26], 2012	Iguchi et al. [22], Moribata et al. [23], 2016	Kim et al. [25], 2016	Han et al. [20], 2018	Oura et al. [27], 2020	Kato et al. [24], 2021
Male sex	240/1,911 (12.6)	12/68 (17.6)	5/112 (4.5)	22/194 (11.3)	39/240 (16.3)	15/189 (7.9)	46/440 (10.5)	28/295 (9.5)	73/373 (19.6)
Age > 70 yr	33/224 (14.7)	-	-	-	-	-	-	-	33/224 (14.7)
Alcohol drinking	38/226 (16.8)	6/40 (15.0)	-	-	32/186 (17.2)	-	-	-	-
Current smoker	41/215 (19.1)	8/36 (22.2)	-	-	33/179 (18.4)	-	-	-	-
PPI use									
Over 1 yr	13/146 (8.9)	-	-	-	-	-	-	13/146 (8.9)	-
Over 2 yr	12/117 (10.3)	-	-	-	-	-	-	12/117 (10.3)	-
Over 3 yr	11/94 (11.7)	-	-	-	-	-	-	11/94 (11.7)	-
H2RA for more than 1 yr	5/27 (18.5)	-	-	-	-	-	-	5/27 (18.5)	-
LDA for more than 1 yr	4/56 (7.1)	-	-	-	-	-	-	4/56 (7.1)	-
<i>H. pylori</i> status									
Neg or eradicated	194/1,850 (10.5)	3/10 (30.0)	7/154 (4.5)	15/177 (8.5)	36/248 (14.5)	10/215 (4.7)	32/369 (8.7)	39/383 (10.2)	52/294 (17.7)
Persistent	90/722 (12.5)	9/72 (12.5)	2/22 (9.1)	13/91 (14.3)	11/82 (13.4)	1/42 (2.4)	18/196 (9.2)	1/28 (3.6)	35/189 (18.5)

Values are presented as n/N (%).

H2RA, histamine-2-receptor antagonist; *H. pylori*, *Helicobacter pylori*; LDA, low-dose aspirin; PPI, proton pump inhibitor.